Share this video  

ESMO WCGIC 2020 | KEYNOTE-966: pembrolizumab, gemcitabine and cisplatin for CCA

Arndt Vogel, MD, Hannover Medical School, Hanover, Germany, discusses the rationale and study design of the KEYNOTE-966 trial (NCT04003636), evaluating pembrolizumab, gemcitabine and cisplatin in cholangiocarcinoma (CCA) patients. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).


Arndt Vogel, MD has had a speaker, consultancy and advisory role at Amgen, Roche, Bayer, Sanofi, BMS, Lilly, Novartis, EISAI, AstraZeneca, Merck, Incyte, Ipsen, PierreFabre, MSD, Sirtex, BTG, Servier, and Terumo.